Sort   by:  
 Page size 
MetabolomicsMulti-omics analysis of thermogenic lipolysis in brown adipocytes

The integration of omics technologies into molecular biological research has transformed it into a field where a system can be investigated as a whole by combining information from multiple biochemical layers. This extension of traditional molecular biology, where various data sources are conside...

2025-11-12 | MTBLS12307 | MetaboLights
ProteomicsMulti-omics analysis of thermogenic lipolysis in brown adipocytes
The integration of omics technologies into molecular biological research has transformed it into a field where a system can be investigated as a whole by combining information from multiple biochemical layers. This extension of traditional molecular biology, where various data sources are considered...
ORGANISM(S): Mus musculus (Mouse) 
2025-09-22 | PXD061570 | Pride
Transomics Brown adipocytes Lipolysis Proteomics Thermogenesis Metabolomics Lc-ms Gc-ms Transcriptomics Multi-omics 
ProteomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
This is part 2 of the same project. Part 1 was just uploaded with the reference: 1-20250110-174238-3123982. Please merge if possible! Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistan...
ORGANISM(S): Homo sapiens (Human) 
2025-08-25 | PXD060046 | Pride
Phosphoproteomics Brca1/2 mutations Ethcd Adp-ribosylation Proteomics Dna damage Parp inhibitors Lc-msms Olaparib resistance 
ProteomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistance to PARPi poses a significant challenge for these therapies, warranting further need for mechanistic insight into PARPi resitance. H...
ORGANISM(S): Homo sapiens (Human) 
2025-08-25 | PXD060950 | Pride
Phosphoproteomics Brca1/2 mutations Ethcd Adp-ribosylation Proteomics Dna damage Parp inhibitors Lc-msms Olaparib resistance 
MetabolomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistance to PARPi poses a significant challenge for long-term efficacy of these therapies, warranting further understanding of mechanisms of...
2026-05-11 | MTBLS12109 | MetaboLights
Sort   by:  
 Page size